CTOs on the Move

CirrusAir Technologies

www.cirrusairtech.com

 
CirrusAir Technologies, LLC designs, develops, manufactures and distributes the ultimate whole-home air purification solution. CirrusAir delivers over 100 years of product innovation through two industry-leading commercial technology partners, the world`s leading commercial industry filter manufacturer and CosaTron, developers of the patented, CosaTron Air Purification System. CirrusAir delivers a range of products designed for every budget and offering best-in-class performance from entry-level filter-only solutions to the flagship CirrusAir Strata Plus product that delivers class 100,000 clean room air quality standards to a residential application.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Similar Companies

Dlubak Corporation

Dlubak Corporation is a Blairsville, PA-based company in the Manufacturing sector.

Glass Crafters Stained Glass

Glass Crafters Stained Glass is a Sarasota, FL-based company in the Manufacturing sector.

Sandaka

Sandaka Inc. is a Kitchener, ON-based company in the Manufacturing sector.

Master Metal Engineering

Master Metal Engineering is a South Bend, IN-based company in the Manufacturing sector.

enVVeno

enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, late clinical-stage medical device company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company`s lead product, the VenoValve®, is a first-in-class surgical replacement venous valve being developed for the treatment of deep venous Chronic Venous Insufficiency (CVI). The Company is also developing a non-surgical, transcatheter based replacement venous valve for the treatment of deep venous CVI called enVVe™. CVI occurs when valves inside of the veins of the leg become damaged, resulting in the backwards flow of blood (reflux), blood pooling in the lower leg, increased pressure in the veins of the leg (venous hypertension) and in severe cases, venous ulcers that are difficult to heal and become chronic. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the leg, and back to the heart and lungs. The VenoValve is currently being evaluated in the SAVVE U.S. pivotal study and the company is currently waiting for regulatory approval to begin the TAVVE first-in-human trial for enVVe.